XORTX Therapeutics Inc
xortx.comWhat Do They Do?
Develops oxypurinol drug candidates for people with gout and polycystic kidney disease.
20-F for FY2025, filed Mar 20, 2026The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the…View ↗
XORLOTM from the XRx-026 program, under our granted formulation patent, is a product candidate intended to be administered once daily to…View ↗
The XRx-008 program is designed to decrease the rate of progression and chronic injury associated with kidney disease in patients with…View ↗
The XRx-008 program is developing a unique proprietary formulation of oxypurinol design to address the therapeutic needs of those…View ↗
How Are They Changing?
Gout program added
The older report centered on an oxypurinol candidate for polycystic kidney disease and other kidney conditions. The latest report also describes a separate oxypurinol program for gout.
20-F for FY2022, filed Apr 28, 2023
Loading...
